


Contents lists available at ScienceDirect

Journal of Molecular Structure

journal homepage: www.elsevier.com/locate/molstr



Bis(Substituted Phenylamino)Glyoxime derivatives: Synthesis, characterization, and antimicrobial evaluation



Amaç Fatih Tuyun^{a,*}, Nilüfer Bayrak^b, Hatice Yıldırım^b, Mahmut Yıldız^c, Emel Mataracı-Kara^d, Berna Ozbek-Celik^d

^a Chemistry Department, Faculty of Science, Istanbul University, Fatih, Istanbul, Turkey

^b Chemistry Department, Engineering Faculty, Istanbul University-Cerrahpasa, Avcilar, 34320, Istanbul, Turkey

^c Chemistry Department, Gebze Technical University, Gebze, 41400, Kocaeli, Turkey

^d Pharmaceutical Microbiology Department, Pharmacy Faculty, Istanbul University, Beyazit, 34116, Istanbul, Turkey

ARTICLE INFO

Article history: Received 3 April 2021 Revised 25 May 2021 Accepted 28 May 2021 Available online 2 June 2021

Keywords: Glyoxime Oxime vic-Dioximes Antibacterial activity Antifungal activity

ABSTRACT

In present work, a set of bis(substituted phenylamino) glyoxime derivatives are presented by the dropwise addition of corresponding primary aryl amines to the dichloroglyoxime (1). Reactions of corresponding primary aryl amines containing various substituents in different positions with dichloroglyoxime (1) gave thirteen compounds. The structural characterization of a set of bis(substituted phenylamino) glyoxime derivatives have been performed on the basis of FTIR, mass, proton, and carbon NMR methods. The crystal structure of compound **3a** has been determined by X-ray diffraction on a single crystal. The NMR spectrum and X-ray data of **3a** show that two hydroxyl groups of dioxime situated at *anti* position. Furthermore, all of the synthesized compounds (**3a-m**) were tested for *in vitro* both antimicrobial activity. The minimal inhibitory concentrations (MICs) against 7 bacteria and 3 yeasts were also determined. Among them, compound **3f** was the most potent compound against *S. aureus* with the value of MIC = 9.76 μ g/mL for the antibacterial activity, in addition to this, compound **3i** has a good potency against *S. aureus* and *C. tropicalis* (MIC = 78.12 μ g/mL) for both antibacterial and antifungal activities, respectively.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

It has been a long time recognized that the vic-dioximes are the important class of amongst the organic compounds having highly versatile applications in a variety of fields, for instance, medicine and bioinorganic chemistry. [1-3] Since the reaction of dimethylglyoxime with Ni(II) was reported for the first time, the complexation studies of these derivatives have been extensively studied comprehensively by a number of scientists due to their utilization as catalysts in chemical processes, biological model compounds such as vitamin B₁₂, and analytical reagents. [4-10] Another good example of an application based on the vic-dioximes is relevant to environmental perspectives. To develop an efficacious extractant that has a considerable influence, especially in the extraction process, on the separation and extraction efficiency used for the removal, separation, and concentration of metal ions from aqueous solutions, vic-dioximes are highly useful synthon. For this purpose, many vic-dioximes possessing different substituents and

* Corresponding author. E-mail addresses: aftuyun@gmail.com, aftuyun@istanbul.edu.tr (A.F. Tuyun). their complexes with different metal ions have been obtained and their extraction features were searched by solvent extraction. [11, 12]

Oximes and their derivatives, which are frequently used in organic synthesis, have a functional role as intermediates in the preparation of various heterocyclic compounds. [15] Compounds of vic-dioxime with two substituents (R-NH-) in 1,2-positions are among the most attractive precursors that are used to synthesize (hetero)cyclic compounds. [13] vic-Dioximes with two substituents (R-NH-) in 1,2-positions containing two carbonyl functional groups, play an important role in many areas. [14, 15] Given the unique chemical and structural properties of those compounds, they have been extensively investigated and applied in material science and medicinal chemistry. [15] Vic-dioximes containing slightly acidic hydroxy groups and slightly basic azomethine groups are amphoteric chelates that can form complexes of various types such as square-pyramidal and octahedral with transition metal ions [14]. The investigation of their coordination chemistry has been exceedingly amplified for different purposes mentioned above. [14, 16-19] Additionally, there are some important reports concerning antimicrobial activities of bis(substituted phenylamino)glyoxime derivatives and their complexes in the literature. [20-22] It has sparked interest in the exploration of their activities in bacteria and fungi, two main types of pathogenic organisms, causing infectious diseases that are one of the ten main reasons for mortality in the world. [23] What is currently the most needed is to make an efficient search for candidates to be assayed as antibacterial agents and highlight the role of organic compounds with a specific skeletons in their activities that have not been explored. Therefore, for a better understanding of antimicrobial properties of bis(substituted phenylamino)glyoxime compounds, this study is going to be a preliminary investigation for the synthesis of new derivatives and this will open the attractive perspectives for the design of new antimicrobial agents containing vic-dioximes.

The first aim of this work is to prepare novel bis(substituted phenylamino)glyoximes (**3a-m**) *via* the reaction of primary aryl amines with various substituents in different positions and dichloroglyoxime (**1**). The second aim is to confirm their structures by spectral data obtained X-ray single crystal, FTIR, NMR, and Mass spectrometers. The third aim is to understand their potential for antimicrobial properties as well.

2. Materials and methods

2.1. Materials and general techniques

General experimental method: All reactions were carried out in oven-dried glassware. The starting material dichloroglyoxime (1) for this research was prepared as reported previously. [24]

Reagents and solvents: All reagents used in the reactions and organic solvents used in the purification step were purchased from commercially available sources and they were used as sold.

Chromatography: Thin layer chromatography (TLC) was applied to monitor the reactions by using Merck silica gel 60 F254 plates and visualized by fluorescence quenching under UV light (254 nm).

Melting points: Melting points (mp) were obtained on a Buchi B-540 melting point without being corrected.

Mass spectra: Mass spectra were measured in ESI mode on a Thermo Finnigan LCQ Advantage MAX MS/MS spectrometer equipped or a BRUKER Microflex LT by MALDI-TOF technique *via* the addition of 1,8,9-anthracenetriol (DIT, dithranol) as matrix.

Infrared spectra: Infrared spectra were measured on Thermo Scientific Nicolet 6700 spectrometer or Alpha T FTIR spectrometer, and ATR on a Perkin Elmer Spectrum 100 Optical FT-IR Spectrometer.

NMR spectra: NMR spectra were recorded in DMSO- d_6 on a VarianUNITY INOVA spectrometer (500 MHz frequency for ¹H and 125 MHz frequency for ¹³C NMR) in ppm. The coupling constants J are given in Hz.

X-Ray Diffraction Analysis: Data for the single crystal compound were obtained with Bruker APEX II QUAZAR three-circle diffractometer. Crystal structure validations and geometrical calculations were performed using the Platon software. [25] Mercury software [26] was used for visualization of the .cif files. The structure has been solved by the Bruker SHELXTL Software Package and refined using OLEX2.refine. [27, 28] The software used for molecular graphics: OLEX2 1.3 [29]; to prepare material for publication: OLEX2 1.3. [29] Data integration and reduction were carried out with SAINT. [30] The crystallographic and structure refinement data are summarized in Table 1. The selected bond lengths, torsion angles, bond angles, and hydrogen-bonding geometry are given in Tables 2-5. The crystallographic data have been deposited at the Cambridge Crystallographic Data Centre, and CCDC reference number is 2072528 for 3a. The data can be obtained available free of charge from http://www.ccdc.cam.ac.uk/conts/retrieving.html.

Table 1					
Crystallog	anhic	data	for	tho	22

Crystanographic	udld	101	the	Jd.

5 8 1	
Identification code	3a
Chemical formula	$C_{16}H_{18}N_4O_4$
Formula weight (g mol ⁻¹)	330.346
Temperature (K)	273.15
Radiation λ (Å)	0.71073
Crystal system	Orthorhombic
Space groups, Z 4	P2 ₁ 2 ₁ 2 ₁ , 4
Unit cell dimensions (Å)	a = 7.1630(15)
	b = 15.071(4)
	c = 15.305(3)
	α , β , $\gamma = 90^{\circ}$
Volume (Å ³)	1652.3(6)
Crystal sizes (mm)	$0.214 \times 0.178 \times 0.138$
dcalc (g cm ⁻³)	1.328
Absorption coefficient (mm ⁻¹)	0.098
Absorption correction, Tmin, Tmax	none, 0.979, 0.987
θ_{\max} , deg	25.010
Goodness-of-fit on F ²	1.045
Index ranges	$-8 \le h \le 8$,
	$-17 \le k \le 17$,
	$-18 \le l \le 10$
Reflections collected	6890
Independent reflections	2872 [Rint = 0.0351, Rsigma = 0.0524]
Final R indices $[I > 2\sigma(I)]$	R1 = 0.0431,
	wR2 = 0.0925
R indices (all data)	R1 = 0.0658,
	wR2 = 0.1038
Refinement method	'\f and \w scans'
Data/restraints/parameters	2872/0/228
Largest diff. peak and hole $(e^{A^{-3}})$	0.18/-0.19

Table 2

Selected bond lengths (Å) with e.s.d (in parentheses) for **3a**.

3a			
02-N1	1.426(3)	C10-C15	1.392(4)
03-N2	1.416(2)	C10-C11	1.373(4)
04-C15	1.357(3)	C2-C3	1.379(4)
04-C16	1.422(3)	C15-C14	1.385(4)
N1-C8	1.284(3)	C11-C12	1.387(4)
N2-C9	1.289(3)	C7-C2	1.384(3)
N4-C8	1.360(3)	C6-C5	1.381(4)
N4-C7	1.410(3)	C14-C13	1.370(5)
01-C2	1.360(3)	C12-C13	1.372(4)
01-C1	1.419(4)	C3-C4	1.377(5)
N3-C9	1.359(3)	C5-C4	1.363(5)
N3-C10	1.415(3)	C6-C5	1.381(4)
C8-C9	1.482(3)	C14-C13	1.370(5)
C7-C2	1.384(3)	C12-C13	1.372(4)
C7-C6	1.381(4)	C3-C4	1.377(5)

2.2. Experimental procedures, analytical, and spectroscopic data

2.2.1. Nucleophilic reaction between dichloroglyoxime and substituted aryl amines

General procedure.

Primary aryl amine (2.2 equiv.) in 3 mL ethanol was added into two necked RB flask that contained a solution of dichloroglyoxime (0.393 g, 2.5 mmol) in 3 mL ethanol (-10 °C). After triethylamine was added, the reaction was allowed to proceed with continued stirring of the solution at room temperature by the time TLC showed the absence of the starting materials (3-4 hours). The resultant solid was gathered by vacuum filtration to give the products (**3a-m**).

 N^1 ', N^2 '-Dihydroxy- N^1 , N^2 -bis(2-methoxyphenyl)oxalamidine (3a).

It was synthesized from dichloroglyoxime (1) and 2methoxybenzenamine (2a) as cream powder according to the general procedure. Yield: 0.63 g, 76%. IR and ¹H NMR spectra were found to be identical with the ones described in literature.

[31] FTIR (ATR): $v \quad \overline{V} = 3400, 3296, 3067, 3022, 2952, 2833, 1655,$

1621, 1597, 1512, 958, 927 cm⁻¹; ¹H NMR (500 MHz, *DMSO-d*₆): δ = 10.75 (s, 2H, -OH), 7.53 (s, 2H, -NH), 6.87-6.83 (m, 6H, Ar-H), 6.77-6.73 (m, 2H, Ar-H), 3.70 (s, 6H, -OCH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 148.5, 142.4, 128.2, 122.3, 120.9, 117.2, 111.2, 56.1 ppm; MS MALDI TOF: (m/z) = 331 (M+H)⁺, Exact Mass. for C₁₆H₁₈N₄O₄ (330.13).

 N^1 ', N^2 '-Dihydroxy- N^1 , N^2 -bis(4-methoxyphenyl)oxalamidine (3b).

It was synthesized from dichloroglyoxime (**1**) and 4methoxybenzenamine (**2b**) as light pink powder according to the general procedure. Yield: 0.53 g, 64%. IR and ¹H NMR spectra were found to be identical with the ones described in literature. [32] FTIR (ATR): v = 3344, 3278, 3011, 2956, 2930, 2833, 1660, 1628, 934 cm⁻¹; ¹H NMR (500 MHz, *DMSO-d*₆): $\delta = 10.15$ (s, 2H, -OH), 7.82 (s, 2H, -NH), 6.71 (d, *J*: 9.2 Hz, 4H, -OCH₂), 6.67

(d, *J*: 9.2 Hz, 4H, -OCH₂), 3.67 (s, 6H, -OCH₃) ppm; ¹³C NMR (125 MHz, *DMSO*- d_6): $\delta = 155.0$, 143.9, 133.4, 121.8, 114.0, 55.6 ppm; MS MALDI TOF: (m/z) = 330 (M)⁺, Exact Mass for C₁₆H₁₈N₄O₄ (330.13).

 N^1 , N^2 -Bis(2-ethoxyphenyl)- N^1 ', N^2 '-dihydroxyoxalamidine (3c).

It was synthesized from dichloroglyoxime (1) and 2ethoxybenzenamine (**2c**) as cream powder according to the general procedure. Yield: 0.48 g, 53%; M.p: 205-206 °C. FTIR (ATR): $\overline{V} \upsilon = 3376, 3240, 2979, 2903, 1625, 1510, 934 \text{ cm}^{-1}$; ¹H NMR (500 MHz, *DMSO-d*₆): $\delta = 10.75$ (s, 2H, -OH), 7.54 (s, 2H, -NH), 6.88-6.84 (m, 2H, Ar-H), 6.82-6.79 (m, 4H, Ar-H), 6.77-6.71 (m, 2H, Ar-H), 3.89 (q, J: 6.9 *Hz*, 4H, -OCH2), 1.29 (t, *J*: 6.9 *Hz*, 6H,

-CH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 147.6, 142.4, 128.4, 122.2, 120.8, 117.1, 112.3, 64.3, 15.1 ppm; MS (ESI+): *m/z* (%) = 359 (100, (M+H)⁺), Exact Mass for C₁₈H₂₂N₄O₄ (358.16).

 N^1, N^2 -Bis(4-ethoxyphenyl)- N^1, N^2 '-dihydroxyoxalamidine (3d).

It was synthesized from dichloroglyoxime (**1**) and 4ethoxybenzenamine (**2d**) as off-white powder according to the general procedure. Yield: 0.58 g, 81%; M.p: 169 °C. FTIR (ATR): $v \quad \overline{V} = 3371, 3173, 3060, 2975, 2930, 2885, 2811, 1636, 1619,$ 969, 921 cm⁻¹. ¹H NMR (500 MHz, *DMSO-d*₆): $\delta = 10.14$ (s, 2H, -OH), 7.81 (s, 2H, -NH), 6.69 (d, *J*: 9.2 Hz, 4H, -OCH₂), 6.65 (d, *J*: 0.2 Hz AH, OCH₂) 2.02 (c, b, 6.0 Hz, AH, OCH₂) 1.28 (c, b, 6.0 Hz, AH)

9.2 Hz, 4H, -OCH₂), 3.92 (q, J: 6.9 Hz, 4H, -OCH₂), 1.28 (t, J: 6.9 Hz, 6H, -CH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 154.2, 143.9, 133.3, 121.8, 114.5, 63.5, 15.2 ppm; MS MALDI TOF: (m/z) = 358 (M)⁺, Exact Mass for C₁₈H₂₂N₄O₄ (358.16).

 N^1 , N^2 -Bis(4-butoxyphenyl)- N^1 ', N^2 '-dihydroxyoxalamidine (3e).

It was synthesized from dichloroglyoxime (1) and 4butoxybenzenamine (**2e**) as off-green powder according to the general procedure. Yield: 0.29 g, 91%; M.p: 136-137 °C. FTIR (ATR): $v \quad \overline{V} = 3366, 3189, 2972, 2905, 1646, 1620, 1509, 890 \text{ cm}^{-1}; {}^{1}\text{H}$

NMR (500 MHz, *DMSO-d*₆): δ = 10.14 (s, 2H, -OH), 7.80 (s, 2H, -NH), 6.69 (d, *J*: 9.2 Hz, 4H, -OCH₂), 6.65 (d, *J*: 9.2 Hz, 4H, -OCH₂), 3.86 (t, *J*: 6.5 Hz, 4H, -OCH₂), 1.68-1.62 (m, 4H, -CH₂), 1.46-1.38 (m, 4H, -CH₂), 0.92 (t, *J*: 7.32 Hz, 6H, -CH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 154.4, 143.9, 133.3, 121.8, 114.5, 67.7, 31.3, 19.2, 14.2 ppm; MS (ESI+): *m/z* (%) = 415 (100, (M+H)⁺), Exact Mass for C₂₂H₃₀N₄O₄ (414.23).

 N^1 ', N^2 '-Dihydroxy- N^1 , N^2 -bis(2,4-dimethoxyphenyl)oxalamidine (3f).

It was synthesized from dichloroglyoxime (**1**) and 2,4dimethoxybenzenamine (**2f**) as brown powder according to the general procedure. Yield: 0.78 g, 80%; M.p: 170 °C. FTIR (ATR): $v \quad \overline{V} = 3404$, 3299, 3015, 2959, 2833, 1653, 1616, 1596, 955, 940 cm⁻¹; ¹H NMR (500 MHz, *DMSO-d₆*): $\delta = 10.45$ (s, 2H, -OH), 7.11 (s, 2H, -NH), 6.79 (d, *J*: 8.8 *Hz*, 2H, Ar-H), 6.40 (d, *J*: 2.5 *Hz*, 2H, Ar-H), 6.35 (dd, *J*: 8.8, 2.5 *Hz*, 2H, Ar-H), 3.68 (s, 6H, -OCH₃), 3.63 (s, 6H, -OCH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 155.8, 150.3, 143.4, 121.7, 119.4, 104.4, 99.0, 56.0, 55.7 ppm; MS MALDI TOF: (m/z) = 390 (M)⁺, Exact Mass for C₁₈H₂₂N₄O₆ (390.15).

 N^1 ', N^2 '-Dihydroxy- N^1 , N^2 -bis(3,4,5-trimethoxyphenyl)oxalamidine (3g).

It was synthesized from dichloroglyoxime (**1**) and 3,4,5trimethoxybenzenamine (**2g**) as white powder according to the general procedure. Yield: 0.48 g, 40%; M.p: 211-212 °C. FTIR (ATR): $\upsilon \quad \overline{V} = 3407, 3348, 2978, 2944, 2848, 2822, 1653, 1631, 1594, 940,$

918 cm⁻¹; ¹H NMR (500 MHz, *DMSO-d*₆): δ = 10.34 (s, 2H, -OH), 7.98 (s, 2H, -NH), 6.13 (s, 4H, Ar-H), 3.60 (s, 12H, -OCH₃), 3.56 (s, 6H, -OCH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 152.7, 144.0, 136.0, 133.0, 98.3, 60.6, 55.9 ppm; MS MALDI TOF: (m/z) = 451 (M+H)⁺, Exact Mass for C₂₀H₂₆N₄O₈ (450.18).

 N^1, N^2 -Bis(2,5-diethoxyphenyl)- N^1 ', N^2 '-dihydroxyoxalamidine (**3h**). It was synthesized from dichloroglyoxime (**1**) and 2,5diethoxybenzenamine (**2h**) as black powder according to the general procedure. Yield: 0.77 g, 76%; M.p: 137-138 °C. FTIR (ATR): v \overline{V} = 3393, 3232, 3096, 2980, 2937, 2878, 1598, 931 cm⁻¹; ¹H NMR

(500 MHz, *DMSO-d*₆): δ = 10.88 (s, 2H, -OH), 7.61 (s, 2H, -NH), 6.71 (d, *J*: 8.8 Hz, 2H, Ar-H), 6.51 (d, *J*: 2.5 Hz, 2H, -Ar-H), 6.32 (dd, *J*: 8.8, 2.5 Hz, 2H, Ar-H), 3.95-3.75 (m, 8H, -OCH₂), 1.38-1.30 (m, 12H, -CH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 153.0, 142.3, 141.5, 129.1, 113.7, 107.0, 103.8, 65.1, 63.4, 15.2, 15.1 ppm; MS MALDI TOF: (m/z) = 447 (M+H)⁺, Exact Mass for C₂₂H₃₀N₄O₆ (446.22).

 N^1, N^2 -Di(benzo [d] [1,3]dioxol-5-yl)- N^1, N^2 '-dihydroxyoxalamidine (3i).

It was synthesized from dichloroglyoxime (1) and 3,4-(methylenedioxy)aniline (2i) as grey powder according to the general procedure. Yield: 0.77 g, 86%; M.p: 210 °C. FTIR (ATR): v \overline{V} = 3374, 3178, 3115, 2893, 2793, 1630, 1487, 1435, 928 cm⁻¹;

¹H NMR (500 MHz, *DMSO-d*₆): δ = 10.26 (s, 2H, -OH), 7.95 (s, 2H, -NH), 6.64 (d, *J*: 8.3 Hz, 2H, Ar-H), 6.37 (d, *J*: 2.2 Hz, 2H, Ar-H), 6.25 (dd, *J*: 8.3, 2.2 Hz, 2H, Ar-H), 5.90 (s, 4H, -OCH₂) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 147.3, 143.8, 142.6, 134.7, 113.0, 108.0, 102.6, 101.1 ppm; MS MALDI TOF: (m/z) = 359 (M+H)⁺, Exact Mass for C₁₆H₁₄N₄O₆ (358.09).

 N^{1} -(2,3-Dihydrobenzo [b] [1,4]dioxin-6-yl)- N^{2} -(2,3-dihydrobenzo [b] [1,4]dioxin-7-yl)- N^{1} ', N^{2} '-dihydroxyoxalamidine (3j).

It was synthesized from dichloroglyoxime (**1**) and 1,4benzodioxan-6-amine (**2j**) as cream powder according to the general procedure. Yield: 0.62 g, 64%; M.p: 141-142 °C. FTIR (ATR): v \overline{V} = 3667, 3341, 3202, 2979, 2904, 1607, 1506, 1062, 888 cm⁻¹; ¹H

NMR (500 MHz, *DMSO-d*₆): δ = 10.20 (s, 2H, -OH), 7.87 (s, 2H, -NH), 6.58-6.56 (m, 2H, Ar-H), 6.38-6.31 (m, 4H, -ArH), 4.17-4.12 (m, 8H, -OCH₂CH₂O-) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 143.6, 143.2, 138.9, 134.0, 116.7, 113.4, 109.3, 64.7, 64.2 ppm; MS (ESI+): *m/z* (%) = 387 (100, (M+H)⁺), Exact Mass for C₁₈H₁₈N₄O₆ (386.12). N¹',N²'-Dihydroxy-N¹,N²-bis(2-isopropylphenyl)oxalamidine (**3k**).

It was synthesized from dichloroglyoxime (1) and 2isopropylbenzenamine (2k) as brown powder according to the general procedure. Yield: 0.57 g, 64%; M.p: 166-167 °C. FTIR (ATR): $\upsilon \quad \overline{V} = 3667, 3404, 3071, 3170, 2966, 2905, 1643, 1596, 947$ cm⁻¹; ¹H NMR (500 MHz, *DMSO-d*₆): $\delta = 10.65$ (s, 2H, -OH), 7.06-6.92 (m, 10H, Ar-H and NH), 2.50-2.43 (m, 2H, -CH), 0.84 (d, l; 6, Hz, 12H, CH), and NH), 2.50-2.43 (m, 2H, -CH), 0.84

(d, *J*: 6.8 *Hz*, 12H, -CH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 144.2, 139.0, 136.3, 125.7, 123.8, 121.2, 115.2, 27.0, 22.9 ppm;

MS (ESI+): m/z (%) = 354 (100, (M)⁺), Exact Mass for $C_{20}H_{26}N_4O_2$ (354.21).

 N^{1} , N^{2} '-Dihydroxy- N^{1} , N^{2} -bis(4-isopropylphenyl)oxalamidine (31).

It was synthesized from dichloroglyoxime (1) and 4isopropylbenzenamine (21) as light brown powder according to the general procedure. Yield: 0.7 g, 79%; M.p: 116-118 °C. FTIR (ATR): $v \quad \overline{V} = 3667, 3380, 3179, 2964, 2905, 1604, 1512, 1056,$

950 cm⁻¹; ¹H NMR (500 MHz, *DMSO-d*₆): δ = 10.31 (s, 2H, -OH), 8.01 (s, 2H, -NH), 6.93 (d, *J*: 8.5 Hz, 4H, Ar-H), 6.73 (d, *J*: 8.6 Hz, 4H, Ar-H), 2.76 (p, *J*: 6.8 Hz, 2H, -CH), 1.14 (d, *J*: 6.8 Hz, 12H, -CH₃) ppm. ¹³C NMR (125 MHz, *DMSO-d*₆): δ = 143.3, 141.8, 137.9, 126.5, 126.3, 119.7, 33.2, 33.0, 24.5, 24.4 ppm; MS (ESI+): *m/z* (%) = 355 (100, (M+H)⁺), Exact Mass for C₂₀H₂₆N₄O₂ (354.21).

 N^1,N^2 -Bis(4-(diethylamino)phenyl)- N^1',N^2' -dihydroxyoxalamidine (3m).

It was synthesized from dichloroglyoxime (1) and 4diethylamino benzenamine (**2m**) as off-white powder according to the general procedure. Yield: 0.99 g, 95%; M.p: 209 °C. FTIR (ATR):

v \overline{V} = 3304, 3107, 2974, 2704, 1643, 944 cm⁻¹; ¹H NMR (500

MHz, *DMSO-d*₆): δ = 9.96 (s, 2H, -OH), 7.53 (s, 2H, -NH), 6.66 (d, *J*: 9.0 *Hz*, 4H, Ar-H), 6.44 (d, *J*: 9.0 *Hz*, 4H, Ar-H), 3.23 (q, *J*: 6.8 *Hz*, 8H, Ar-H), 1.03 (t, *J*: 6.8 *Hz*, 12H, -CH₃) ppm; ¹³C NMR (125 MHz, *DMSO-d*₆): δ (ppm) = 144.5, 143.9, 129.3, 122.5, 112.6, 44.4, 12.8 ppm; MS MALDI TOF: (m/z) = 410 (M-2H)⁺, Exact Mass for C₂₂H₃₂N₆O₂ (412.26).

2.3. In vitro antimicrobial activity

2.3.1. Determination of Minimum Inhibitory Concentrations (MIC)

The microbroth dilutions technique was performed to determine antimicrobial activity against Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 4352, Pseudomonas aeruginosa ATCC 27853, Proteus mirabilis ATCC 14153, Enterococcus faecalis ATCC 29212, Candida albicans ATCC 10231, Candida parapsilosis ATCC 22019, and Candida tropicalis ATCC 750 according to the Clinical Laboratory Standards Institute (CLSI) recommendations. [33, 34] Mueller-Hinton broth for bacteria and RPMI-1640 medium for yeast strain were used as the test medium. Serial twofold dilutions ranging from 2500 μ g/mL to 4.88 μ g/mL were prepared in the medium. The inoculum was prepared using a 4-6 h broth culture of each bacteria type and 24 h culture of yeast strains adjusted to a turbidity equivalent to 0.5 McFarland standard, diluted in broth media to give a final concentration of 5×10^5 cfu/mL for bacteria and 5 \times 10³ cfu/mL for yeast in the test tray. The trays were covered and placed into plastic bags to prevent evaporation. The trays containing Mueller-Hinton broth were incubated at 35°C for 18-20 h while the trays containing RPMI-1640 medium were incubated at 35°C for 46-50 h. The MIC was defined as the lowest concentration of compound giving complete inhibition of visible growth. As a control, antimicrobial effects of the solvents were investigated against test microorganisms. According to the values of the controls, the results were evaluated. The MIC values of the compounds are shown in Table 6.

3. Results and discussion

3.1. Chemistry


The starting material dichloroglyoxime (1) for this study was prepared as reported previously, following a modified method of van der Peet shown in Scheme 1. [24] The glyoxal (40% w/v) was reacted with hydroxylamine hydrochloride in the presence of triethylamine to prepare glyoxime in water at -10 °C. After this

step, we have used *N*-Chlorosuccinimide in portions for chlorination of glyoxime in order to obtain dichloroglyoxime (**1**) in DMF at -10 °C as reported earlier. [24] Thirteen different bis(substituted phenylamino) glyoxime compounds (**3a-m**) have been synthesized which are examples of substituted *vic*-dioximes and summarized in Scheme 2. These derivatives were obtained according to the literature by the reactions of a wide range of primary aryl amines bearing divergent substituents with dichloroglyoxime (**1**) in ethanol at -10 °C. In most cases, the products obtained were solid in good yields and could be collected by filtration as the only purification method. ¹H and ¹³C NMR, FTIR, and MS spectral data were used to determine the structures of these new compounds given in the Experimental Section.

FTIR data provide evidence for principal functional groups on the structure of the bis(substituted phenylamino)glyoxime derivatives (**3a-m**). Some of the characteristic bands such as OH and NH vibrations have been observed for these compounds. [17] In the FTIR spectral data of the synthesized compounds in this paper, the bands at expected areas pertain to N-H and O-H stretching vibrations, respectively, agreeing with previously reported values of the substituted vic-dioximes. [18]

Additional structural information can be deduced from both proton and carbon NMR spectra. The structures of 3a-m are further confirmed by the study of proton magnetic resonance spectra in dimethyl sulfoxide- d_6 in which the hydroxyl and amine protons of these compounds resonated as two singlets at very similar values around 10.5 and 7.5 ppm, respectively. The aromatic protons of phenylamino moiety were observed at between 6.5-7.5 ppm. The proton-decoupled ¹³C NMR spectral data were also in harmony with the structure of **3a-m**. The chemical shifts belong to the substituents on the aryl ring; methoxy, ethoxy, butoxy, *i*-propyl, *N*,*N*diethyl, methylenedioxy, and ethylenedioxy derivatives were as expected in the ¹³C NMR spectra of molecules. Assignment of the exchangeable protons of bis(substituted phenylamino)glyoxime was confirmed based on data from D₂O exchange, after the exchangeable protons peaks have clearly disappeared or decreased in intensity. From the present mass spectral data, it is concluded molecular ion peaks of glyoxime derivatives, which confirmed the proposed structures.

NMR spectra of the bis(substituted phenylamino)glyoxime compounds (3a-m) were taken first for structure determination. Bis(substituted phenylamino)glyoxime structure has NH and OH groups. The peaks around 9.5-10.5 ppm and 7.5-8.0 ppm belonged to the N-OH and NH group protons at ¹H NMR. As proof, when taken the D₂O exchange spectra of them, these peaks were disappeared. The compounds 3b, 3d, 3e, 3l, and 3m had a common splitting pattern of two para-substituted rings in the aromatic region. Looked at the ¹H NMR of **3***l* and **3**, in the aromatic region, two doublet patterns were seen at around 6.93, and 6.73 ppm with Jortho 8.5 Hz for **31** and 6.66 ppm and 6.44 ppm with Jortho 9.0 Hz for 3m (Figure 1a). However, for the compound 3b, 3d, and 3e these two doublets were too close to each other at 6.69 ppm $(J_{ortho}$ 9.2) Hz) and 6.65 ppm $(J_{ortho}$ 9.2 Hz) (Figure 1b). In the ¹H NMR spectra of 3f, 3h, and 3i, there were three splitting patterns of aromatic protons. It can be seen Jortho and Jmeta values for these structures. Proton Ha has no neighboring proton so it was just split by meta proton \mathbf{Hb} as a doublet pattern with J_{meta} value around 2.5 Hz. Proton Hb was split by ortho proton Hc and meta proton Ha as a doublet of doublets (dd) pattern with Jortho and Jmeta values around 8.8 Hz and 2.5 Hz, respectively. Looked at proton Hc, it can be determined easily it was split by neighboring proton Hb as a doublet pattern with J_{ortho} value around 8.8 Hz (Figure 1c). In the ¹³C NMR spectrum, the two symmetrically carbon of glyoxime backbone (C=NOH) were seen at around 156-143 ppm. The structure 3g showed only two peaks of Carom-OMe at around 144 and 136 ppm because of the symmetry even though it has three



Fig; 1. The splitting patterns of substituted phenyl groups.

methoxy groups (OMe). The carbons (=CH) of para-alkoxy substituted phenyl groups were at around 113 and 122 ppm at ¹³C NMR. When looked at the carbons (=CH) peaks of ortho-alkoxy substituted phenyl, the signals were seen at around 122, 120, 117, and 112 ppm as four peaks.

3.2. X-ray crystallographic analysis

An x-ray diffraction structural study was carried out on bis(substituted phenylamino)glyoxime on an automatic diffractometer using λ MoK radiation using 6890 reflections. The structure of 3a was confirmed by X-ray diffraction analysis of a single crystal obtained by slow evaporation from an ethyl alcohol solution. The unit cell parameters of the crystal of 3a compound, $C_{16}H_{18}N_4O_4$ at 273 K, which has three axes of different lengths (a = 7.1630, b = 15.071, c = 15.305) and whose axes intersect at 90 degrees (α , β , $\gamma = 90^{\circ}$) with space groups P2₁2₁2₁, is compatible to ortothorhombic crystal system. In the X-Ray study, it is determined that the structure of **3***a* has anti configurations of the oxime groups in symmetrically substituted glyoxime compound. The bond lengths of C8 -C9 (1.482 Å), N1-C8 (1.284 Å), and N2-C9 (1.289 Å) in the structure of **3a** are specific for glyoximes, featuring conjugation between the π systems (C=NOH) in the dioxime fragment. [35] The length of the N4-C8 and N3-C9 bonds between the sp³ hybridized N and sp^2 hybridized C atoms in compound **3a** is about 1.360 Å, which is greater than 1.28 Å between the sp² hybridized N and the C atom of the disubstituted glyoxime compound. This is in line with the rule that bonds between sp²-sp² hybridized atoms are shorter than bonds between sp²-sp³ hybridized atoms. The lengths of the aromatic C-C bonds in the phenyl group range from 1.363 to 1.402 Å. The O1-C1 and O4-C16 bond lengths of methoxy groups in the phenyl rings are 1.419 and 1.422 Å, respectively. The ORTEP drawing of the **3a** was reported at a 50% probability level in Figure 2. The crystallographic and structure refinement data for compound **3a** is summarized in Table 1. The molecular geometry with bond lengths and angles in the dioxime fragment is given in Tables 2 and 4. The C-C-C bond angles of the phenyl ring of 3a are very close to 120.8° which supports structures involving sp² hybridized atoms.

The torsion angle of two phenyl amino groups bonded to the dioxime fragment is N4-C8-C9-N3 is -54.3°. Also, the dihedral angle between two oxime groups (N1-C8-C9-N2) is -59.3°. The N1-C8-C9-N3 and N2-C9-C8-N4 torsion angles are 124.0° and 122.4°, respectively. O2-N1-C8-NC9 (178.85°) and O3-N2-C9-C8 (-179.15°)





Fig. 2. ORTEP drawings of the 3a at 50% probability level.

show that two OH groups are anti position. Moreover, the NMR spectrum of **3a** shows OH peaks as a singlet at 10.75 ppm and this singlet peak proves the *anti*-configuration. [36] From the literature, this kind of isomeric structure is called *anti* (E,E). [14, 18, 37, 38] Some other torsion angles of compound **3a** given in Table 3 support the structure. In terms of bond distances and angles, the molecular geometry of **3a** is compatible with the expected.

In the structure of **3a**, there are hydrogen acceptor and donor groups. Therefore, the x-ray data shows possible both intermolecular and intramolecular hydrogen bonds. The corresponding distance and angle of hydrogen bonds are given in Table 5. All crystallo-



Compounds	R ¹	R ²	R ³	R ⁴	R⁵
3a	OMe	н	н	н	н
3b	н	н	OMe	н	н
3c	OEt	н	н	н	н
3d	н	н	OEt	н	н
3e	н	н	OBut	н	н
3f	OMe	н	OMe	н	н
3g	н	OMe	OMe	OMe	н
3h	OEt	н	н	OEt	н
3i	н	00	CH ₂ O	н	н
3j	н	OCH	I ₂ CH ₂ O	н	н
3k	i-propyl	н	н	н	н
31	н	н	<i>i</i> -propyl	н	н
3m	н	н	N,N-diethyl	н	н

graphic data of the compounds are presented in the supplementary material (Supplementary Material, SM).

3.3. Antimicrobial activity

All of the synthesized compounds (**3a-m**) were involved in a study to evaluate for their *in vitro* antimicrobial activity by comparing Ceftazidime, Cefuroxime-Na, Cefuroxime, Amikacin, Clotrimazole, and Amphotericin B. Tested Gram-negative were *P. aerugi*-

Table 3

Torsion angles (°) for 3a.

3a			
02-N1-C8-C9	178.95(17)	N1-C8-C9-N3	124.0 (2)
02-N1-C8-N4	-2.9(2)	N2-C9-C8-N4	122.4(2)
03-N2-C9-C8	-179.15 (18)	N4-C7-C2-C3	179.7(3)
03-N2-C9-N3	-2.7 (2)	01-C2-C3-C4	178.2(3)
N1-C8-N4-C7	159.0(2)	N4-C8-C9-N3	-54.3(2)
N2-C9-N3-C10	171.6(2)	04-C15-C14-13	178.9(3)

Table 4

Selected bond angles (°) for with e.s.d (in parentheses) for $\mathbf{3a}$.

3a			
C16-04-C15	117.7(2)	C6-C7-C2	119.4(3)
C8-N1-O2	109.81(18)	C15-C10-N3	118.1(2)
C9-N2-O3	110.22(19)	C11-C10-C15	119.9(2)
C7-N4-C8	125.2(2)	C5-C4-C3	120.1(3)
C1-01-C2	118.2(3)	C3-C2-01	125.5(3)
C10-N3-C9	125.3(2)	C3-C2-C7	119.9(3)
N4-C8-N1	126.1(2)	C7-C2-01	114.6(2)
C9-C8-N1	114.6(2)	C14-C15-O4	125.7(3)
C9-C8-N4	119.3(2)	C14-C15-C10	119.5(3)
N3-C9-N2	125.3(2)	C12-C11-C10	120.6(3)
C8-C9-N2	114.3(2)	C5-C6-C7	120.2(3)
C8-C9-N3	120.4(2)	C13-C14-C15	119.6(3)
C2-C7-N4	119.2(2)	C4-C3-C2	120.2(3)
C6-C7-N4	121.3(2)	C4-C5-C6	120.2(3)

Table 5

Hydrogen-bonding geometry (Å, °) for 3a.

D-HA	D-H	HA	DA	D-HA
02-H2N1	0.90 (3)	2.56 (3)	3.132 (3)	122 (3)
02-H2N2	0.90 (3)	1.93 (3)	2.804 (3)	163 (3)
03-H302	0.820 (13)	1.984 (9)	2.783 (2)	165 (2)
N3-H3A03	0.860 (3)	2.247 (3)	2.572 (3)	102.4 (2)

nosa, E. coli, K. pneumoniae, and *P. mirabilis*, whereas Gram-positive bacteria were *S. aureus, S. epidermidis*, and *E. faecalis*. The tested fungi were *C. albicans, C. parapsilosis*, and *C. tropicalis*. The obtained results reflected variable antimicrobial activity and are given in Table 6.

Among the synthesized and tested compounds, compound **3f** had the best MIC value (MIC = 9.76 μ g/mL) against *S. aureus*. In addition, **3i** showed good potency against *S. aureus* and *C. tropicalis* (MIC = 78.12 μ g/mL). Both test-cultures *S. epidermidis* and *S. aureus* appeared to be susceptible to most of the synthesized compounds with MIC values of between 9.76–1250 μ g/mL. The test-cultures *C. albicans* showed not to be susceptible to all of the synthesized compounds. The biological data also reveal that both compounds **3f** and **3i** were the most active among the synthesized compounds; they have both antibacterial and antifungal activities. Although **3m** did not show activity against fungi, it has moderate activity against two important pathogen microorganisms of the Gram-negative Enterobacteriaceae family (*Klebsiella pneumoniae* and *Escherichia coli*) and also Gram-positive microorganisms (*Staphylococcus aureus* and *Staphylococcus epidermidis*).

3.4. Structure-Activity Relationship (SAR) study

When we analyzed the structural features with their MIC values of the synthesized compounds by modification of various positions in the aryl amine moiety, the obtained results from the antibacterial activity are quite interesting because of the correlation against *S. aureus* strains. When all molecules were analyzed against the Gram-negative bacteria and the Gram-negative bacteria in addition to fungi, it seems difficult to abstract definite structure-activity re-

						Microor	tani cm c				
							INITCI UUI BAIII SIIIS				
			Gram-negati	ative Bacteria			Gram-positive Bacteria	ria	Fungi		
		P. aeruginosa	E. coli	K. pneumoniae	P. mirabilis	E. faecalis	S. epidermidis	S. aureus	C. albicans	C. parapsilosis	C. tropicalis
MIC Values (<i>u.g</i> /mL)	3a			,	,	1	,	,	1		
	3b	625	625	ı	ı	ı	625	1250	ı	ı	ı
	3с					625	1250				
	3d										
	3e										
	3f				625		1250	9.76		625	156.2
	3g	625									
	3h							1250			312.5
	3i						1250	78.12		312.5	78.12
	3j	625					625	625			
	3k							156.2			
	31							312.5			
	3m		312.5	625			625	156.2			
	Reference	2.4	4.9	4.9	2.4	128	9.8	4.0	4.9 Clotri-	0.5	1.0
	antimicrobials	Ceftazidime	Cefuroxime-Na	Cefirroxime-Na	Cefurovime-Na	Amikacin	Cefuroxime	Amikacin	mazole	Amphotericin B	Amphotericin R

lationship except that *S. aureus* since there is not any sufficient data. We noticed that there is no significant activity against the rest of the microorganisms when we analyzed the effect of the position and presence of the substituent(s) on the phenyl ring in tested molecules. Among them, **3f** containing two alkoxy groups on the phenyl ring had the best antibacterial activity against *S. aureus*. The two substituents in a cyclic structure (**3i** and **3j**) was unfavorable in relation to the antibacterial activity against *S. aureus* when compared with the **3f**. Leading the loss of activity has been noticed for the **3g** containing the three alkoxy groups on the phenyl ring. Thus, it may be concluded that the presence of two substituents, in particular alkoxy groups, on the phenyl ring is vital for obtaining good activity against *S. aureus*.

4. Conclusion

In this paper, thirteen novel bis(substituted phenylamino) glyoximes were obtained, characterized by different spectral methods, and evaluated their antimicrobial activities using broth microdilution techniques. Assignment of the exchangeable protons of bis(substituted phenylamino)glyoxime was confirmed based on data from D₂O exchange, after the exchangeable protons peaks have clearly disappeared or decreased in intensity. From the X-ray analysis of **3a**, two OH groups of dioxime were placed anti position due to the torsion angles of O2-N1-C8-NC9 (178.85°) and O3-N2-C9-C8 (-179.15^o). The structure of **3a** is an anti- dioxime as demonstrated by X-ray and NMR spectra. Testing in vitro these new compounds for their antimicrobial activity against several type strains revealed that the compound **3f** was the most potent compound against S. aureus (MIC = 9.76 μ g/mL) for the antibacterial activity, whereas compound **3i** has a good potency against *S. aureus* and *C. tropicalis* (MIC = 78.12 μ g/mL) for the antibacterial and antifungal activities, respectively. Although 3m did not show activity against fungi, it could be evaluated for further studies due to its moderate efficiency for both gram-negative and gram-positive microorganisms. The simple access to bis(substituted phenylamino)glyoxime derivatives should pave the way for their applications in different areas.

Credit author statement

The corresponding author is responsible for ensuring that the descriptions are accurate and agreed by all authors.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.molstruc.2021.130812.

References

- L. Musilova, K. Kuca, Y.S. Jung, D. Yun, In vitro oxime-assisted reactivation of paraoxon-inhibited human acetylcholinesterase and butyrylcholinesterase, Clin. Toxicol. 47 (6) (2009) 545–550.
- [2] K. Kuca, L. Musilova, J. Palecek, V. Cirkva, M. Paar, K. Musilek, M. Hrabinova, M. Pohanka, J.Z. Karasova, D. Jun, Novel bisquaternary oximes-reactivation of acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon, Molecules 14 (12) (2009) 4915–4921.
- [3] M.J. Prushan, A.W. Addison, R.J. Butcher, Pentadentate thioether-oxime macrocyclic and quasi-macrocyclic complexes of copper(II) and nickel(II), Inorg. Chim. Acta 300 (2000) 992–1003.
- [4] C. Demetgul, S. Serin, Synthesis and characterization of a new vic-dioxime derivative of chitosan and its transition metal complexes, Carbohyd. Polym. 72 (3) (2008) 506–512.

- [5] G.N. Schrauzer, Organocobalt chemistry of vitamin B12 model compounds (Cobaloximes), ACC Chem. Res. 1 (1968) 97.
- [6] Y. Gok, H. Kantekin, H. Alp, M. Ozdemir, Synthesis and Characterization of the Free Ligand 5,6/13,14-Dibenzo-9,10-Benzo(15-Crown-5)-2,3-Bis(Hydroxyimino)-7,12-Dioxo-1,4,8,11-tetraazacyclotetra-decane and its mono and Tri nuclear-complexes, Z Anorg. Allg. Chem. 621 (7) (1995) 1237–1242.
- [7] E. Tas, M. Aslanoglu, A. Kilic, Z. Kara, Synthesis, characterization and redox properties of three new vic-dioximes and their nickel(II) metal complexes, Transit. Metal. Chem. 30 (6) (2005) 758–764.
- [8] B. Mercimek, E. Ozcan, A.I. Pekacar, The Synthesis and Ni(li), Co(li), Cu(li), Zn(li), Cd(li) and Uo2(Vi) complexes of N,N'-Bis(2-Tolyl)Diaminoglyoxime and N,N'-Bis(4-Tolyl)Diaminoglyoxime, Syn. React. Inorg. Met. 25 (9) (1995) 1571–1579.
- [9] S. Nemeth, L. Simandi, Homogeneous catalytic-oxidation of ortho-phenylenediamine by dioxygen in the presence of Cobaloxime(li) derivatives - synthesis of substituted 2h-Benzimidazoles, J. Mol. Catal. 14 (1) (1982) 87–93.
- [10] L. Tschugaeff, Ueber ein neues, empfindliches Reagens auf Nickel, L. Chem. Ber. 38 (1905) 2520.
- [11] R. Gup, A.D. Beduk, Synthesis and characterization of complexes of Ni(II), Co(II), and Cu(II) with four 4-aminobenzoate derivatives of unsymmetrical vicdioximes, Syn. React. Inorg. Met. 32 (6) (2002) 1043–1057.
- [12] L.R.M. Paping, T.P.M. Beelen, M. Mols, R. Prins, Extraction of Copper(li) and Nickel(li) by cyclic Trioximes and cyclic Furazan oximes, Polyhedron 3 (4) (1984) 479–484.
- [13] P.L. van der Peet, T.U. Connell, C. Gunawan, J.M. White, P.S. Donnelly, S.J. Williams, A click chemistry approach to 5,5 '-Disubstituted-3,3 '-Bisisoxazoles from Dichloroglyoxime and alkynes: luminescent organometallic iridium and rhenium bisisoxazole complexes, J. Org. Chem. 78 (14) (2013) 7298–7304.
- [14] F. Yuksel, A.G. Gurek, M. Durmus, I. Gurol, V. Ahsen, E. Jeanneau, D. Luneau, New insight in coordination of vic-dioximes: Bis- and tris(E,E-dioximato) Ni(II) complexes, Inorg. Chim. Acta 361 (8) (2008) 2225–2235.
- [15] M.A. Motaleb, A.A. Selim, Dioximes: Synthesis and biomedical applications, Bioorg. Chem. 82 (2019) 145–155.
- [16] R.H. Khanmiri, A. Moghimi, A. Shaabani, H. Valizadeh, S.W. Ng, Diaminoglyoxime as a versatile reagent in the synthesis of bis(1,2,4-oxadiazoles), 1,2,4-oxadiazolyl-quinazolines and 1,2,4-oxadiazolyl-benzothiazinones, Mol. Divers 18 (4) (2014) 769–776.
- [17] G. Irez, O. Bekaroglu, The synthesis and complex-formation of some new substituted amino and Diaminoglyoximes, Syn. React. Inorg. Met. 13 (6) (1983) 781–797.
- [18] A. Kakanejadifard, A. Khajehkolaki, B. Ranjbar, H. Naderi-Manesh, Synthesis of new dioximes and tetraoximes from reaction of aminothiophenoles with dichloroglyoxime, Asian J. Chem. 20 (4) (2008) 2937–2946.
- [19] A.R. Ghiasvand, R. Ghaderi, A. Kakanejadifard, Selective preconcentration of ultra trace copper(II) using octadecyl silica membrane disks modified by a recently synthesized glyoxime derivative, Talanta 62 (2) (2004) 287–292.
- [20] I. Babahan, E.P. Coban, H. Biyik, Synthesis, characterisation and antimicrobial activities of vic-dioxime derivatives containing heteroaromatic hydrazone groups and their metal complexes, Maejo Int. J. Sci. Tech. 7 (1) (2013) 26–41.
- [21] I. Babahan, F. Eyduran, E.P. Coban, N. Orhan, D. Kazar, H. Biyik, Spectroscopic and biological approach of Ni(II), Cu(II) and Co(II) complexes of 4-methoxy/ethoxybenzaldehyde thiosemicarbazone glyoxime, Spectrochim. Acta A 121 (2014) 205–215.
- [22] I. Babahan, E.P. Coban, A. Ozmen, H. Biyik, B. Isman, Synthesis, characterization and biological activity of vic-dioxime derivatives containing benzaldehydehydrazone groups and their metal complexes, Afr. J. Microbiol. Res. 5 (3) (2011) 271–283.
- [23] WHO, Methods and Data Sources for Country-Level Causes of Death 2000-2015 (2017).
- [24] PL C.T. Peet, C Gunawan, JM White, PS Donnelly, SJ Williams, A Click Chemistry Approach to 5,5'-Disubstituted-3,3'-Bisisoxazoles from Dichloroglyoxime and Alkynes: luminescent organometallic iridium and rhenium bisisoxazole complexes, J. Org. Chem. 78 (2013) 7298–7304.
- [25] A.L. Spek, Structure validation in chemical crystallography, Acta Crystallogr. D 65 (2009) 148–155.
- [26] C.F. Macrae, P.R. Edgington, P. McCabe, E. Pidcock, G.P. Shields, R. Taylor, M. Towler, J. van De Streek, Mercury: visualization and analysis of crystal structures, J. Appl. Crystallogr. 39 (2006) 453–457.
- [27] L.J. Bourhis, O.V. Dolomanov, R.J. Gildea, J.A.K. Howard, H. Puschmann, The anatomy of a comprehensive constrained, restrained refinement program for the modern computing environment-Olex2 dissected, Acta Crystallographica a-Foundat. Adv. 71 (2015) 59–75.
- [28] G.M. Sheldrick, SHELXT integrated space-group and crystal-structure determination, Acta Crystallographica a-Foundat. Adv. 71 (2015) 3–8.
- [29] O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, OLEX2: a complete structure solution, refinement and analysis program, J. Appl. Crystallogr. 42 (2009) 339-341.
- [30] SAINT, Version 8.34A, Bruker (2013).
- [31] N.E. Alexandrou, D.N. Nicolaides, Synthesis and spectroscopic study of dioxamidoxime derivatives, Chem. Chron. (1972) 39–43.
- [32] H. Bati, M. Tas, M. Macit, B. Bati, The synthesis and characterization of new substituted aminoglyoximes and their complexes with some transition metals, Synth. React. Inorg. Met.-Org. Chem. 28 (9) (1998) 1561–1569.

- [33] Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of yeastsApproved Standard-2th ed. M27-A2, CLSI, Wayne, PA, 1997.
- [34] Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobicallyApproved standard M7-A7, 7th ed., CLSI, Wayne, PA, 2006.
- 7th ed., CLSI, Wayne, PA, 2006.
 [35] L.F. Chertanova, A.I. Yanovskii, Y.T. Struchkov, V.F. Sopin, O.A. Rakitin, T.I. Godovikova, L.I. Khmelnitskii, An X-Ray-diffraction structural investigation of glyoxime derivatives .4. The molecular and crystal-structure of Dicyanoglyoximes and Dimesitylglyoximes, J. Struct. Chem. 30 (6) (1989) 968–972.
- [36] S. Duman, M. Sekerci, Formation of novel amino vic-dioxime complexes of Cu(II), Ni(II), Co(II) and Cd(II) of 1,3-Dioxalane groups containing the oxime moiety: thermal, magnetic and spectral studies, J. Chem. Soc. Pakistan 34 (3) (2012) 621–625.
- [37] A.I. Stepanov, D.V. Dashko, A. Astrat'ev, 1,2-Di(4-R-furazan-3-yl)glyoximes: synthesis by the reduction of 3,4-Bis(4-R-furazan-3-yl)furoxans and study of the reactivity of these compounds, Chem. Heterocycl. Com+ 49 (5) (2013) 776–790.
- [38] T. Hokelek, A. Zulfikaroglu, H. Bati, 1-(2,6-Dimethylphenylamino)propane-1,2-dione dioxime, Acta Crystallogr. E 57 (2001) 01247–01249.